EUCTR2011-005637-38-IT进行中（未招募）不适用
PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS - TREnd_trial
FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS0 个研究点开始时间: 2012年3月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease. 2. ER positive tumor = 10% 3. HER2 negative breast cancer by FISH or IHC (IHC 0,1+, 2+ and/or FISH HER2: CEP17 ratio < 2.0,) 4. Progression of advanced breast cancer on first or second line endocrine therapy for advanced breast cancer 4. Paraffin-embedded tumor available for centralized assessment of biomarkers (either archived primary tumor tissue or biopsy of a metastatic site) 5. Measurable disease according to RECIST 1.1 or bone only disease (bone only disease is allowed if measurable or evaluable). Previously irradiated lesions are deemed measurable only if progression is documented at the site after completion of radiation. 6. Females, 18 years of age or older. 7. Postmenopausal status defined as: • Prior bilateral surgical oophorectomy; • Amenorrhea and age > 60 years; • Age <60 years and amenorrhea for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and estradiol in the postmenopausal ranges. 8. Eastern Cooperative Oncology Group (ECOG) Performance status 0 -2 9. Resolution of all acute toxic effects of prior therapy or surgical procedures to CTCAE grade >1 (except alopecia or other toxicities not considered a safety risk for the patient). 10. Adequate organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. Unstable brain metastases (stable brain metastases not requiring steroids are allowed); presence of spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. 2. Major surgery within 3 weeks of first study treatment. 3. Prior treatment with: • More than one line of chemotherapy for advanced breast cancer • More than two lines of endocrine treatment for advanced breast cancer • Any CDK inhibitor. 4. Current treatment with: • Any experimental treatment on another clinical trial; • Therapeutic doses of anticoagulant (Low dose anticoagulants for deep vein thrombosis prophylaxis are allowed. Aspirin is permitted.) 5. Current use or anticipated need for: • food or drugs that are known strong CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, tilithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine • drugs that are known strong CYP3A4 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John’s Wort) 6. Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. 7. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE grade =2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism. 8. Active inflammatory bowel disease or chronic diarrhea. Short bowel syndrome. Upper gastrointestinal surgery including gastric resection. 9. Known hypersensitivity to letrozole, anastrazole, exemestane or fulvestrant, or to any of their excipients. 10. Known human immunodeficiency virus infection; active Hepatitis C, active hepatitis B 11. Severe medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with interpretation of study results and, in the investigator opinion, would make the subject inappropriate for this study.
研究者
相似试验
进行中（未招募）
不适用
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableMetastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.Classification code 10055113EUCTR2004-000572-14-DKAventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)162
进行中（未招募）
1 期
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableMetastatic Breast Cancer Patients after failure to Anthracyclines, Taxanes and Capecitabine.Classification code 10055113EUCTR2004-000572-14-ESAventis Pharmaceuticals, Inc.162
进行中（未招募）
不适用
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableEUCTR2004-000572-14-BEAventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)162
进行中（未招募）
不适用
Reparixin following islet transplantatiointrahepatic islet transplantationMedDRA version: 14.0Level: PTClassification code 10058846Term: Pancreas islet cell transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-019424-31-DEDompé s.p.a.10
进行中（未招募）
不适用
A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type 1 diabetes mellitus. - Reparixin in Pancreatic Islet TransplantatioEUCTR2010-019424-31-ITDOMPE` s.p.a.10